Royalty Pharma Stock Earnings Reports

Royalty Pharma delivered a strong start to 2026 with double-digit momentum in recurring cash flows and active capital deployment. Key financial results: portfolio receipts grew 10% and royalty receipts (recurring cash flows) grew 13% in Q1; portfolio cash flow (adjusted EBITDA less net interest paid) was $722 million; deployed $528 million of capital in the quarter; repurchased 1 million shares for $50 million and raised the dividend by 7%. The company announced ~$1.25 billion of transactions across three therapies and expanded its R&D co-funding activity (notably deals with J&J and Teva), positioning co-funding as a large and scalable market opportunity tied to >$1 trillion projected global R&D spend. Portfolio highlights include acquisition of a royalty on Jazz/BeOne’s Ziihera (potential blockbuster with >$2B peak sales in consensus), Revolution Medicines’ daraxonrasib Phase III results in pancreatic cancer (near-doubling of overall survival), and approvals/readouts across multiple programs (Denali Avlayah approval, Myqorzo positive pivotal results, other positive trials and filings). Financial position remains strong: cash of $586M, investment-grade debt of $9.2B with ~12-year duration, leverage ~2.9x, undrawn $1.8B revolver and ~ $4B total financial flexibility; Fitch upgraded rating to BBB. Management raised full-year 2026 portfolio receipts guidance to $3.325B–$3.45B and provided Q2 receipts guidance of $740M–$760M, noting expected headwinds from certain LOEs and biosimilar launches but strong underlying growth. The company emphasized ongoing investments in global platform expansion (Asia/China) and AI/data capabilities to enhance diligence and partner value, while maintaining disciplined return targets (ROIC ~14%, ROIE ~20%, target IRRs on development-stage investments in the low double digits). Arbitration with Vertex is expected to be resolved around mid-2027.